Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Definiens Establishes Advisory Board

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
Renowned industry experts to advise Definiens on clinical digital pathology market.

Definiens announced it has appointed an Advisory Board comprising renowned industry experts and visionaries in digital pathology. As part of its market expansion strategy, Definiens established the new Board to provide independent advice on trends and opportunities in tissue diagnostics and clinical digital pathology.

Members of the Advisory Board include:

•    Ron A. Andrews, President, Medical Sciences, Life Technologies and former CEO of Clarient and CEO of GE Molecular Diagnostics
•    Prof. Uwe Bicker, Dean of the Medical Faculty Mannheim, University of Heidelberg and a member of the board of directors of Sanofi SA
•    Prof. Manfred Dietel, Director, Institute of Pathology, Charité Berlin and chairman of the German Society for Pathology
•    Eric F. Glassy, M.D., Medical Director, Pathology, Inc.and chairman of the Digital Pathology Working Group of the College of American Pathologists
•    Prof. Gerd Binnig, Founder and CTO, Definiens (Moderator)

“Definiens is working to advance personalized medicine by contributing to the development of next generation diagnostics, and bringing those novel diagnostics into clinical practice. Our innovations have the potential to transform daily clinical practice for the benefit of both patients and pathologists, particularly in oncology,” said Thomas Heydler, CEO of Definiens. “We will greatly benefit from the wealth of experience of the Advisory Board members while expanding our business into tissue diagnostics and clinical digital pathology.”

As part of its goal to guide Definiens during the company’s expansion, the Advisory Board will discuss trends in digital pathology and highlight opportunities for image and data analysis to revolutionize clinical practice in pathology. Specific topics of discussion will include pathology workflow, tissue diagnostic test development, personalized medicine and next-generation cancer treatment, as well as future technology and market requirements. Definiens founder and Nobel laureate, Professor Gerd Binnig, will catalyze the discussions.

“With the novel opportunities enabled by digital pathology, progress in diagnosing and treating cancer will be accelerated. The visionary power and expertise brought together in the Definiens Advisory Board will be invaluable on our path towards bringing advanced image analysis to clinical pathology,” said Prof. Gerd Binnig, Founder and CTO of Definiens.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Indivumed, Definiens Partner
Partnership aims to unlock the power of tumor tissue for drug discovery and development.
Wednesday, July 20, 2016
Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics
Big data approach bridges the gap between genomics and personalized medicine.
Saturday, June 28, 2014
Definiens Expands Management Team to Develop the Clinical Market
Company announces appointment of Pablo Jordan and Rebecca Berghorn.
Tuesday, October 29, 2013
Definiens Appoints Chief Marketing Officer, Merrilyn Datta, Ph.D.
Dr. Datta brings a wealth of experience in marketing and her expertise will be critical as Definiens expands its leadership in the life sciences and tissue diagnostics industries.
Tuesday, April 09, 2013
Definiens Strengthens Leadership with Key Appointment
Former Aperio executive and digital pathology market expert, Dr. Martin Stuart, joins executive team.
Thursday, February 02, 2012
Definiens Image Analysis Technology Improves Accuracy in Scoring Her2/neu in Breast Cancer Biopsies
New multi-dimensional image analysis platform aids diagnosis and treatment of breast cancer.
Wednesday, June 03, 2009
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
Blood-brain Barrier on a Chip
Researchers from Vanderbilt University have developed a microfluidic device to study the blood-brain barrier.
Genetic Links to Brain Cancer Cell Growth
Researchers discover clues to tumour behaviour from genetic differences between brain cancer cells and normal tissue cells.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Secret Phenotypes: Disease Devils in Invisible Details
Algorithmic deep phenotyping exposes masses of hidden traits and possible subtle genetic connections relevant to unseen influences on disease.
Hunting the Missing Link Between Genetics and the Environment
The International Phenome Centre Network (IPCN) works to transform healthcare through phenomics - the dynamic interactions between our genes and our environment.
Gene Limits Desire To Drink Alcohol
Research teams have identified a gene variant that suppresses the desire to drink alcohol.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!